J
Jyoji Nakagawara
Researcher at Memorial Hospital of South Bend
Publications - 171
Citations - 4206
Jyoji Nakagawara is an academic researcher from Memorial Hospital of South Bend. The author has contributed to research in topics: Stroke & Modified Rankin Scale. The author has an hindex of 27, co-authored 167 publications receiving 3576 citations. Previous affiliations of Jyoji Nakagawara include Iwate Medical University & Tohoku University.
Papers
More filters
Journal ArticleDOI
Effects of Extracranial–Intracranial Bypass for Patients With Hemorrhagic Moyamoya Disease: Results of the Japan Adult Moyamoya Trial
Susumu Miyamoto,Takashi Yoshimoto,Nobuo Hashimoto,Yasushi Okada,Ichiro Tsuji,Teiji Tominaga,Jyoji Nakagawara,Jun C. Takahashi,Keisuke Yamada,Yasutake Tomata,Tsuguya Fukui,Yasuo Fukuuchi,Takashi Ohmoto,Yasuo Kuwabara,Izumi Nagata,Junichi Ono,Toshio Machida,Ryuji Sakakibara,Kanji Yamane,Shinji Okita,Toru Iwama,Yasuhiko Kaku,Nobuhito Saito,Hidenao Fukuyama,Kiyohiro Houkin,Satoshi Kuroda,Ichiro Yabe,Fumio Moriwaka,Akira Ogawa,Kuniaki Ogasawara,Kenji Yoshida,Kiyotaka Fujii,Masaru Yamada,Kimitoshi Sato,Tsugio Akutsu,Sen Yamagata,Shigekazu Takeuchi,Kentaro Hayashi,Nobutaka Horie,Kazuo Yamada,Toshiaki Osato,Toshiichi Watanabe,Kaori Honjo,Kazuya Sako,Hiroyuki Nakase,Shoichiro Kawaguchi,Fumihiko Nisimura,Junichi Yamao,Hiroaki Naritomi,Tooru Inoue,Hiroshi Abe,Akifumi Suzuki,Tatsuya Ishikawa,Yoshinori Akiyama,Toshihiko Suenaga,Miki Fujimura,Shinji Nagahiro,Masaaki Uno,Kyoko Nishi,Junichiro Satomi,Yoshikazu Okada,Akiji Kawashima,Kohji Yamaguchi,Yukiko Tsutsumi +63 more
TL;DR: Although statistically marginal, Kaplan–Meier analysis revealed the significant difference between surgical and nonsurgical group, suggesting the preventive effect of direct bypass against rebleeding.
Journal ArticleDOI
Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset Japan Alteplase Clinical Trial (J-ACT)
Takenori Yamaguchi,Etsuro Mori,Kazuo Minematsu,Jyoji Nakagawara,Kazuo Hashi,Isamu Saito,Yukito Shinohara +6 more
TL;DR: In this paper, the authors performed a clinical trial with 0.6 mg/kg, which is lower than the internationally approved dosage of 0.9 mg/ kg, aiming to assess the efficacy and safety of alteplase in acute ischemic stroke for the Japanese.
Journal ArticleDOI
Ischemic Stroke and Incomplete Infarction
TL;DR: This work alerts physicians to the potential development of incomplete brain infarctions in patients with intracranial arterial occlusions and recognizes incomplete infarcts is particularly important in the context of stroke therapy with thrombolytic and neuroprotective agents.
Journal ArticleDOI
Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice The Japan post-Marketing Alteplase Registration Study (J-MARS)
Jyoji Nakagawara,Kazuo Minematsu,Yasushi Okada,Norio Tanahashi,Shinji Nagahiro,Etsuro Mori,Yukito Shinohara,Takenori Yamaguchi +7 more
TL;DR: The J-MARS data suggest that 0.6 mg/kg intravenous alteplase within 3 hours of stroke onset could be safe and effective in routine clinical practice for the Japanese.
Journal ArticleDOI
Effects of 0.6 mg/kg Intravenous Alteplase on Vascular and Clinical Outcomes in Middle Cerebral Artery Occlusion Japan Alteplase Clinical Trial II (J-ACT II)
Etsuro Mori,Kazuo Minematsu,Jyoji Nakagawara,Takenori Yamaguchi,Makoto Sasaki,Teruyuki Hirano +5 more
TL;DR: Early recanalization of an occluded middle cerebral artery can be provoked by 0.6 mg/kg intravenous alteplase and may induce a favorable clinical outcome, similar to that previously reported with the 0.9-mg/kg dose.